Mousera has returned to investors for cash. The Silicon Valley startup emerged from stealth mode last year with $10 million in VC funding and ex-Pfizer CEO Jeff Kindler on its board. Now, it has added a further $20 million in Series B funding and given a few more hints at what it is furtively building using the cash.
Novartis has opened a new front in its push into digital health. The latest move sees the Big Pharma bring its navigation app for visually impaired people to Apple and Google's smartwatch platforms.
10X Genomics has started shipping its hotly tipped long-read sequencing technology, GemCode Platform. And the first batch of buyers of the $75,000 machines includes some big names, with the Broad Institute among the organizations to already have a GemCode Platform installed.
A congressman is taking aim at perceived flaws in FDA's long-awaited, much-discussed guidance on the use of Twitter.
Foundation Medicine and IMS Health have teamed up to offer a precision medicine service. The alliance brings together Foundation Medicine's cancer genomics database and IMS' real-world evidence platform, a combination the partners think can enable the effective use of more targeted therapies.
Biopharma companies may finally be fully embracing the wealth of clinical trial technologies now available. The trend, according to the analyst who observed it, is partly a result of the pressure on R&D teams to hustle drugs to market as quickly as possible while also generating the pharmacoeconomic data payers now demand.
Google has signed up a high-profile collaborator to work on its burgeoning cloud genomics platform. The agreement will see the Broad Institute of MIT and Harvard work with Google to create new tools that pair their respective strengths in data analysis and cloud computing, starting with the offering of GATK as a service.
Google has revealed its pitch to establish wearables as a cornerstone of clinical trials. The wristband health tracker is aimed squarely at the clinical trial and healthcare sectors, setting it apart from consumer-focused rivals from Apple and Fitbit.
Eisai has become the latest in a long line of companies to look to IT outsourcing for cost savings. The drugmaker has handed responsibility for the maintenance, operation and monitoring of much of its IT infrastructure in Japan and the U.S. to Accenture in a pair of long-term deals.
The Securities and Exchange Commission (SEC) is going after the biotech-focused hacking ring known as FIN4. Details of the group first emerged last year when security company FireEye reported on how it was breaking into email accounts in search of stock-moving news nuggets, a modus operandi that has put it in the crosshairs of the SEC.
Zymergen raised $44 million in a Series A round to develop its data-driven approach to improving microbe-based manufacturing.
The FDA has overhauled its Risk Evaluation and Mitigation Strategies website to make it easier to find up-to-date information. The new version moves details of whether REMS apply to a drug, what components are in place and when they were last updated to the forefront, ending the need for users to dig through a database to find information.
GlaxoSmithKline is placing a $95 million wager on the significance of the "living genome," a term for the noncoding DNA that appear to regulate how genes function in different cells, states of disease and environments. The initiative will lean heavily on computer scientists, who will make up some of the 40 to 80 researchers that will be hired using the Glaxo funds.
With the clinical trial community gathering for DIA 2015, eClinical tech vendors have been rolling out releases about their new tools, hires and deals. Here we round up a batch of notable news, including a new hire at Clinical Ink, deals for DocuSign and a visit to the FDA by Nextrials.
PatientsLikeMe has pulled off a major coup. The patient-networking website added FDA to its roster of A-list clients this week in a deal that sees it provide the regulator with access to the 110,000 adverse event reports filed by its 350,000 members.
The Washington Post has taken a look at how hospitals are using genetic tumor databases to find exceptional responders to cancer drugs.
Sanford-Burnham Medical Research Institute is about to apply its robotics and 3-D modeling skills to the discovery of molecules to treat heart failure. Takeda is bankrolling the two-year program as part of its broader collaboration The Sanford Consortium for Regenerative Medicine.
The long-heralded, little-seen death of the laptop may actually be happening at Allergan. A push to restrict staffers to one device and the arrival of Microsoft Office on the Apple iPad reportedly drove a 10% year-on-year decline in laptop use at the company.
An electronic health record-enabled data dive has turned up links between proton pump inhibitors and a 16% to 20% increase in the risk of heart attack.